Abstract
The placebo response is associated with a positive expectation of recovery. Recent studies in mice uncovered a potential underlying mechanism of placebo effects, by demonstrating the involvement of the dopaminergic mesolimbic pathway, previously implicated in reward expectation, in immune modulation. Yet, it is not known whether an analogous brain-immune regulatory mechanism exists in humans, and whether it employs conscious positive expectations. Here, we employed fMRI-neurofeedback to train healthy participants to increase their reward mesolimbic activity by using self-chosen mental strategies, followed by Hepatitis B Virus (HBV) vaccination. We found that stronger Ventral Tegmental Area (VTA) activity, but not control regions activation, was associated with higher post-vaccination HBV antibody titer. Interestingly, higher VTA activity before vaccination was associated with mental strategies characterized by positive expectation. Thus, our results establish a relationship between reward system activity, positive expectation and immunity in humans and reveal a potential neuropsychological mechanism for non-invasive immune modulation.
Competing Interest Statement
T.H. is the Chief Medical Scientist and Chair of advisory board in GrayMatters Health Co Haifa Israel. T.H., A.R., N.L. and T.K. have a filed patent related to the topic of this paper in the United States Patent and Trademark Office (application number: 17/435.906; Title of Invention: Neurofeedback and Induction of an Immune Response). The other authors report no competing interests.
Clinical Trial
NCT03951870
Funding Statement
This study was funded by Joy Ventures foundation and by KAMIN program in the Israeli ministry of innovation. N.L. would like to thank the Teva Bio-Innovation Forum.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
the IRB of the Tel-Aviv Sourasky Medical Center gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability statement
Requests for de-identified data can be directed at the corresponding author (Talma Hendler, talma{at}tlvmc.gov.il). All requests for data sharing will be reviewed by the Tel-Aviv Sourasky Medical Center Institutional Review Board (IRB) committee, to verify whether the request is subject to any intellectual property or confidentiality obligations. Requests will be reviewed on the basis of scientific merit, ethical review, available resources and regulatory requirements, and will be responded within 90 days. After approval of a proposal, anonymized individual-level data will be made available for reuse in accordance with the signed consent IRB form. A signed data access agreement with the collaborator is required before accessing shared data.